FDA Approves Brexucabtagene Autoleucel for Relapsed or Refractory B-cell Precursor Acute Lymphoblastic Leukemia
On October 1, 2021, the Food and Drug Administration approved brexucabtagene autoleucel (Tecartus, Kite Pharma, Inc.) for adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). Read more.